

Cover Story
																																	Free
By Paul Goldberg and Matthew Bin Han Ong
FDA may have escaped the devastating cuts in President Trump's first budget proposal, while NIH ended up taking the brunt of its fury.
In Brief


Drugs & Targets


Trending Stories
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Trump cuts IVF drug deal with Merck in exchange for tariff exemption
- Science advocates organize march in DC to demand impeachment of RFK Jr.
- Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
 ctMoniTR project aims to improve efficiency in development of intermediate endpoints
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
 
            

















